After one HBV flop, Assembly Biosciences forced to drop a hepatitis asset amid safety woes
After one HBV flop, Assembly Biosciences forced to drop a [...]
After one HBV flop, Assembly Biosciences forced to drop a [...]
Exit of Avidity CMO on cusp of first clinical trial [...]
HebeCell lands $53M, Chinese collaborator to make a splash in [...]
After cutting dose because of deaths, Astellas pauses gene therapy [...]
J&J’s HIV vaccine fails phase 2b, extending long wait for [...]
GSK, Korean biotech SK go head-to-head against AstraZeneca’s COVID-19 shot [...]
A year after a death and accompanying trial hold, Poseida [...]
The descent of van de Stolpe: Galapagos CEO exits after [...]
Brain cancer biotech Ziopharm snaps up new CEO from Kuur [...]
Pfizer’s abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, [...]